Table 2.
Patient and trials characteristics associated with AEs Tolerability score in univariate and multivariate analyses
| Factors | Univariate analysis | Multivariate analysis |
|---|---|---|
| At baseline | ||
| Age | p=0.88379 | |
| Sex | p=0.717 | |
| Type of primary tumour | p2=0.439/p3=0.690/p4=0.166 | p2=0.6612/p3=0.7686/p4=0.100 |
| Number of previous chemotherapies | p=0.0521 | p=0.1360 |
| Number of previous targeted therapies | p=0.0532 | p=0.0781 |
| Previous phase 1 trial enrolment | p=0.0647 | p=0.6824 |
| At study completion | ||
| Age | p=0.17470 | |
| Sex | p=0.39370 | |
| Type of primary tumour | p2=0.56729/p4=0.42879 | |
| Number of previous chemotherapies | p=0.00755** | p=0.0234* |
| Number of previous targeted therapies | p=0.635 | |
| Previous phase 1 trial enrolment | p=0.374 | |
| Worst AE grade | p=0.0049** | p=0.0153* |
| Trial duration | p=0.647 | |
| Type of drug | p=0.48045 |
p2 refers to the comparison of lung cancers with CRCs, p3 refers to the comparison of breast cancers with CRCs and p4 refers to the comparison of other types with CRCs.
*p<0.05, **p<0.01.
AE, adverse event; CRC, colorectal cancer.